Back to top
more

Eli Lilly (LLY)

(Delayed Data from NYSE)

$952.74 USD

952.74
2,060,174

-1.43 (-0.15%)

Updated Aug 23, 2024 04:00 PM ET

After-Market: $950.50 -2.24 (-0.24%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value F Growth B Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 37% (93 out of 251)

Industry: Large Cap Pharmaceuticals

Better trading starts here.

Zacks News

Sweta Killa headshot

5 ETFs to Make the Most of Eli Lilly's Strength

Impressed by Eli Lilly's (LLY) blowout earnings, several analysts raised their target price on the stock.

International Markets and Lilly (LLY): A Deep Dive for Investors

Review Lilly's (LLY) international revenue performance and how it affects the predictions of financial analysts on Wall Street and the future prospects for the stock.

Nektar's (NKTR) Q2 Earnings Lag Estimates, Revenues Top

Nektar (NKTR) reports a wider-than-expected loss in the second quarter of 2024 while revenues beat estimates. Stock falls in after-hours trading.

Kinjel Shah headshot

Pharma Stock Roundup: LLY, NVO, BAYRY Q2 Earnings, MRK's New Deal & Other Updates

Eli Lilly (LLY), Novo Nordisk (NVO) and Bayer (BAYRY) announce second-quarter results. Merck (MRK) expands existing co-development deal with partner Daiichi Sankyo.

Company News for Aug 9, 2024

Companies in The News Are: CYBR, PH, LLY, DDOG

Twilio and Floor & Decor Holdings have been highlighted as Zacks Bull and Bear of the Day

Twilio and Floor & Decor Holdings have been highlighted as Zacks Bull and Bear of the Day

Ethan Feller headshot

Eli Lilly: The Next $1 Trillion Market Cap Stock?

Eli Lilly showcased the exceptional strength of its business during its quarterly earnings meeting on Thursday morning

Eli Lilly (LLY) Q2 Earnings Top, Mounjaro, Zepbound Drive View

Eli Lilly (LLY) beats second-quarter estimates for earnings and sales. It raises its guidance for 2024 on strong demand for Mounjaro and Zepbound.

Continuing Claims Hit Highest Since Nov 2021

Continuing Claims Hit Highest Since Nov 2021

Jobless Claims Decline, Pre-Markets in the Green

It???s a big day for Wall Street as the much-awaited Jobless Claims numbers are out, which could be a major factor in market moves for the rest of the week.

Compared to Estimates, Lilly (LLY) Q2 Earnings: A Look at Key Metrics

Although the revenue and EPS for Lilly (LLY) give a sense of how its business performed in the quarter ended June 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Eli Lilly (LLY) Surpasses Q2 Earnings and Revenue Estimates

Lilly (LLY) delivered earnings and revenue surprises of 48.48% and 14.99%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Amgen (AMGN) Stock Down Despite Q2 Earnings & Sales Beat

Amgen (AMGN) beats second-quarter 2024 estimates for earnings and sales. It tightens its revenue and earnings guidance range for 2024. Stock falls.

Derek Lewis headshot

Eli Lilly (LLY) & Novo Nordisk (NVO) Earnings: A Closer Look

Given their underperformance in 2024, a positive set of quarterly results could easily push both stocks higher.

Can Mounjaro & Zepbound Drive Eli Lilly (LLY) Q2 Earnings?

Investor focus is likely to be on the sales numbers of Lilly's (LLY) tirzepatide medicines Mounjaro and Zepbound.

Kanishka Das headshot

Will These 5 Medical Stocks Surpass Q2 Earnings Forecasts?

Let's look at five biotech and drug companies, AMGN, GILD, LLY, VTRS & NVO, due to release their second-quarter 2024 results this week.

Kinjel Shah headshot

Should You Buy, Sell or Hold Lilly (LLY) Ahead of Q2 Earnings?

Investor focus is likely to be on the sales numbers of Lilly's (LLY) tirzepatide medicines Mounjaro and Zepbound.

Lilly (LLY) Q2 Earnings on the Horizon: Analysts' Insights on Key Performance Measures

Besides Wall Street's top -and-bottom-line estimates for Lilly (LLY), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended June 2024.

Company News for Aug 2, 2024

Companies In The Article Are: LLY,MGM,SO and TRP

Eli Lilly (LLY) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

Lilly (LLY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Here is What to Know Beyond Why Eli Lilly and Company (LLY) is a Trending Stock

Lilly (LLY) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Is First Trust Health Care AlphaDEX ETF (FXH) a Strong ETF Right Now?

Smart Beta ETF report for FXH

Incyte's (INCY) Q2 Earnings Lag Estimates, Revenues Top

Incyte's (INCY) second-quarter 2024 earnings miss estimates while revenues beat the same. The company raises the bottom end of the 2024 revenue guidance for its lead drug, Jakafi.

Merck (MRK) Q2 Earnings and Revenues Top Estimates

Merck (MRK) delivered earnings and revenue surprises of 5.56% and 1.35%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?